ST-1646

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameST-1646
Drug Alias Nameangiogenesis inhibitors (Sigma-Tau)heparin derivative (Sigma-Tau)alpha-v/beta-5 antagonists (Sigma-Tau)p-PST.sUST-1646 +[7] 
ClassificationSmall molecules
Mechanisms of ActionFibroblast growth factor 2 inhibitorsHeparin modulatorsIntegrin alpha-V/beta-3 antagonists +[4] 
TargetsFibroblast growth factor 2Integrin alpha-V/beta-3
Therapy Area/IndicationsAngiogenesis disorderNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSigma-Tau Industrie Farmaceutiche Riunite Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSigma-Tau Industrie Farmaceutiche Riunite Spa
Active IndicationsN/A
Inactive IndicationsAngiogenesis disorderNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A